Prostate Cancer Highlights from ASCO GU 2022

Episode 1 March 08, 2022 00:38:59
Prostate Cancer Highlights from ASCO GU 2022
COR2ED Medical Education
Prostate Cancer Highlights from ASCO GU 2022

Mar 08 2022 | 00:38:59

/

Show Notes

COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States discuss ‘Prostate Cancer Highlights from ASCO GU 2022’ in this GU CONNECT podcast.

In this podcast, the experts review data from a number of key plenary sessions from ASCO GU 2022 and discuss potential implications for clinical practice. The ARASENS trial is covered first which looked at triplet therapy in the form of ADT plus docetaxel and darolutamide in patients with metastatic castration sensitive prostate cancer (mCSPC). Discussion then moves to two trials investigating the combination of abiraterone acetate with PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) patients with and without homologous recombination repair (HRR) mutations: the PROpel trial with olaparib and the MAGNITUDE trial with rucaparib. 

Neal and Alicia also discuss a fascinating presentation by Dr. Daniel Spratt which looked at digitising histopathology slides and using Artificial Intelligence (AI) to inform on the likelihood of disease progression and whether or not patients needed androgen deprivation therapy (ADT)

Finally, Alicia discusses a number of posters which she felt made an impact, including one on PSA responses in the TITAN and SPARTAN trials and a secondary analysis from the VISION trial looking at treatment related adverse events, amongst others. 

Other Episodes

Episode 3

April 05, 2023 00:22:48
Episode Cover

Case-based discussion on which mCSPC patients benefit from early treatment intensification

COR2ED Medical Education: Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC)...

Listen

Episode 1

February 28, 2022 00:13:11
Episode Cover

Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO...

Listen

Episode 1

September 20, 2022 00:23:43
Episode Cover

GI CONNECT Update from ESMO 2022 Ep 1: lower GI cancer highlights

COR2ED Medical Education: In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny...

Listen